• 동의신경정신과학회지
• /
• 제22권4호
• /
• pp.157-168
• /
• 2011

Objectives : In this case report, we will present a patient with dementia with Lewy bodies improved by application of oriental medical treatments. Methods : A 82 year-old female patient has been suffered by dementia with Lewy bodies for 7~8 years. We treated the patient with Herbal medication and acupuncture. The effects of treatment were measured by MMSE-K (Mini-Mental State Examination-K). Results : As a result of oriental treatments, the quality of sleep was improved, also the level of cognition was improved. Conclusions : These results suggest that oriental treatments have an effect on Dementia with Lewy bodies.

• 생물정신의학
• /
• 제23권2호
• /
• pp.41-47
• /
• 2016

Dementia with Lewy bodies (DLB) is the second most common causes of dementia. It can exhibit a variety of clinical symptoms including cognitive decline, cognitive fluctuation, visual hallucinations, parkinsonism, REM sleep behavior disorder, hypersensitivity to neuroleptics and autonomic dysfunctions. Despite more well-known criteria for DLB, there are often misdiagnosis and inappropriate treatment. It gives a lot of clinical burden to the clinician as well as to patients and families. When reducing the misdiagnosis, the burden of all will be reduced. The special concern and solicitation are needed in order not to miss the diagnosis when the cardinal features of DLB may not be volunteered by patients and the caregivers. To control the symptoms, clinicians must find and reduce drugs that can have the negative effects on DLB symptoms. There is limited evidence about specific interventions but available data suggest cholinesterase inhibitors improve the cognitive and behavioral symptoms and menmantine slightly improves the global impression.

• 대한핵의학회지
• /
• 제37권1호
• /
• pp.13-23
• /
• 2003

Neurodegenerative disorders cause a variety of dementia including Alzheimer disease, frontotemporal dementia, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy, and Huntington's disease. PET scan is useful for early detection and differential diagnosis of these dementing disorders. Also, it provides valuable information about clinico-anatomical correlation, allowing better understanding of function of brain. Here we discuss recent achievements PET studies regarding these dementing disorders. Future progress in PET technology, new tracers, and image analysis will play an important role in further clarifying the disease pathophysiology and brain functions.

• Nuclear Medicine and Molecular Imaging
• /
• 제41권2호
• /
• pp.102-111
• /
• 2007

Dementia is a major burden for many countries including South Korea, where life expectancy is continuously growing and the proportion of aged people is rapidly growing. Neurodegenerative disorders, such as, Alzheimer disease, dementia with Lewy bodies, frontotemporal dementia, Parkinson disease, progressive supranuclear palsy, corticobasal degeneration, Huntington disease, can cause dementia, and cerebrovascular disease also can cause dementia. Depression or hypothyroidism also can cause cognitive deficits, but they are reversible by management of underlying cause unlike the forementioned dementias. Therefore these are called pseudodementia. We are entering an era of dementia care that will be based upon the identification of potentially modifiable risk factors and early disease markers, and the application of new drugs postpone progression of dementias or target specific proteins that cause dementia. Efficient pharmacologic treatment of dementia needs not only to distinguish underlying causes of dementia but also to be installed as soon as possible. Therefore, differential diagnosis and early diagnosis of dementia are utmost importance. F-18 FDG PET is useful for clarifying dementing diseases and is also useful for early detection of the diseases. Purpose of this article is to review the current value of FDG PET for dementing diseases including differential diagnosis of dementia and prediction of evolving dementia.

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 2003년도 추계학술대회 및 총회
• /
• pp.24.1-24.1
• /
• 2003

• Fisheries and Aquatic Sciences
• /
• 제25권3호
• /
• pp.117-139
• /
• 2022

Synucleinopathies such as Parkinson's disease (PD) are incurable neurodegenerative conditions characterised by the abnormal aggregation of α-synuclein protein in neuronal cells. In PD, fibrillary synuclein aggregation forms Lewy bodies and Lewy neurites in the substantia nigra and cortex on the brain. Dementia with Lewy bodies and multiple system atrophy are also associated with α-synuclein protein abnormalities. α-synuclein is one of three synuclein proteins, and while its precise function is still unknown, one hypothesis posits that α-synuclein propagates from the enteric nervous system through the vagus nerve and into the brain, resulting in synucleinopathy. Studies on synucleinopathies should thus encompass not only the central nervous system but must necessarily include the gut and microbiome. The zebrafish (Danio rerio) is a well-established model for human neuronal pathologies and have been used in studies ranging from genetic models of hereditary disorders to neurotoxin-induced neurodegeneration as well as gut-brain-axis studies. There is significant genetic homology between zebrafish and mammalian vertebrates which is what makes the zebrafish so amenable to modelling human conditions but in the case of synucleinopathies, the zebrafish notably does not possess an α-synuclein homolog. Synuclein orthologs are present in the zebrafish however, and transgenic zebrafish that carry human α-synuclein have been generated. In addition, the zebrafish is a highly advantageous model and ideal replacement for reducing the use of mammalian models. This review discusses the application of the zebrafish as a model for synucleinopathies in efforts to further understand synuclein function and explore therapeutic strategies.

• BMB Reports
• /
• 제52권6호
• /
• pp.349-359
• /
• 2019

After the first research declaring the generation of human induced pluripotent stem cells (hiPSCs) in 2007, several attempts have been made to model neurodegenerative disease in vitro during the past decade. Parkinson's disease (PD) is the second most common neurodegenerative disorder, which is mainly characterized by motor dysfunction. The formation of unique and filamentous inclusion bodies called Lewy bodies (LBs) is the hallmark of both PD and dementia with LBs. The key pathology in PD is generally considered to be the alpha-synuclein (${\alpha}$-syn) accumulation, although it is still controversial whether this protein aggregation is a cause or consequence of neurodegeneration. In the present work, the recently published researches which recapitulated the ${\alpha}$-syn aggregation phenomena in sporadic and familial PD hiPSC models were reviewed. Furthermore, the advantages and potentials of using patient-derived PD hiPSC with focus on ${\alpha}$-syn aggregation have been discussed.

• Annals of Clinical Neurophysiology
• /
• 제22권2호
• /
• pp.82-91
• /
• 2020

Electroencephalography (EEG) produces time-series data of neural oscillations in the brain, and is one of the most commonly used methods for investigating both normal brain functions and brain disorders. Quantitative EEG analysis enables identification of frequencies and brain activity that are activated or impaired. With studies on the structural and functional networks of the brain, the concept of the brain as a complex network has been fundamental to understand normal brain functions and the pathophysiology of various neurological disorders. Functional connectivity is a measure of neural synchrony in the brain network that refers to the statistical interdependency between neural oscillations over time. In this review, we first discuss the basic methods of EEG analysis, including preprocessing, spectral analysis, and functional-connectivity and graph-theory measures. We then review previous EEG studies of brain network characterization in several neurological disorders, including epilepsy, Alzheimer's disease, dementia with Lewy bodies, and idiopathic rapid eye movement sleep behavior disorder. Identifying the EEG-based network characteristics might improve the understanding of disease processes and aid the development of novel therapeutic approaches for various neurological disorders.

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 2004년도 추계학술대회 및 총회
• /
• pp.395.1-395.1
• /
• 2004

• 정신신체의학
• /
• 제15권2호
• /
• pp.73-80
• /
• 2007

지난 여러 해 동안 치매에서 나타나는 안구운동기능부전에 대해 수많은 논문이 발표되었다. 안구운동검사는 뇌의 기능을 평가하는 비침습적인 검사이며, 치매와 연관된 뇌의 이상을 밝혀내는데 유용한 방법이다. 저자는 치매와 연관된 안구운동이상에 대한 지금까지의 여러 연구들을 고찰해 보았다. 알쯔하이머병에서는 신속안구운동의 잠재기가 증가하고 정확도가 감소하며 항신속안구운동의 오류가 증가 한다. 전측두엽 치매 환자에서는 반사성 신속안구운동 억제의 장애와 항신속안구운동 잠재기와 오류 증가 소견이 나타난다. 그리고 헌팅톤병에서는 수의적인 신속안구운동의 시작 지연, 느린 신속안구운동, 항신속안구운동의 오류와 잠재기 증가 소견이 나타난다. 파킨슨병 치매와 루이체 치매 환자에서는 반사성 신속안구운동과 복합성 신속안구운동 실행 장애가 보고되었다. 크로이츠펠트-야콥 병에 관한 연구는 많지 않으며, 안구운동장애는 치매 증상이 명확해진 이후인 질병의 말기에 나타나고, 이차적으로 소뇌와 전정기관을 침범하게 된다고 한다. 진행성 핵상마비에서는 느린 신속안구운동과 측정저하 신속안구운동이 수직방향주시 장애가 오기 이전에 나타나는 경우가 많다. 수의적인 눈꺼풀 운동의 기능부전도 진행성 핵상마비의 특징적인 증상이다. 결론적으로 치매 환자들은 다양한 비정상적인 안구운동장애를 나타내며 이는 피질, 피질하 기능부전과 연관되어 있다. 치매 환자의 안구운동장애에 대한 다음 단계 연구는 치매에서 나타나는 임상적인 증상이 뇌의 어떤 부위 이상 때문에 발생하는지를 좀 더 명확하게 밝히는 것이 될 것이다.